Cost-effectiveness analysis of ceftazidime-avibactam as definitive treatment for treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infection

BACKGROUND: Ceftazidime-avibactam (CAZ-AVI) is a novel antibiotic that has been confirmed in the United States and China for use in patients with carbapenem-resistant Klebsiella pneumoniae (CRKP) bloodstream infection (BSI). However, the cost-effectiveness of CAZ-AVI is unknown in China. This study...

Descripción completa

Detalles Bibliográficos
Autores principales: Kong, Wenqiang, Yang, Xueting, Shu, Yunfeng, Li, Shiqin, Song, Bihui, Yang, Kun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Public Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011158/
https://www.ncbi.nlm.nih.gov/pubmed/36926178
http://dx.doi.org/10.3389/fpubh.2023.1118307

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011158/
https://www.ncbi.nlm.nih.gov/pubmed/36926178
http://dx.doi.org/10.3389/fpubh.2023.1118307

Ejemplares similares